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Background: The effect of intravenous amiodarone on spatial and transmural dispersion of ventricular
repolarization in patients receiving cardiac resynchronization therapy (CRT) remains unclear.
Methods: We studied 14 patients with nonischemic heart failure who received CRT with a deﬁbrillator,
experienced electrical storm and were treated with intravenous amiodarone. Each patient underwent
12-lead electrocardiography (ECG) and 187-channel repolarization interval-difference mapping electro-
cardiography (187-ch RIDM-ECG) before and during the intravenous administration of amiodarone
infusion.
Results: A recurrence of ventricular tachyarrhythmia was observed in 2 patients during the early period
of intravenous amiodarone therapy. Intravenous amiodarone increased the corrected QT interval
(from 470752 ms to 508755 ms, P¼0.003), but it signiﬁcantly decreased the QT dispersion (from
107735 ms to 49727 ms, P¼0.001), T peak–T end (Tp–e) dispersion (from 86717 ms to 28728 ms,
P¼0.001), and maximum inter-lead difference between corrected Tp–e intervals as measured by using
the 187-ch RIDM-ECG (from 83713 ms to 50719 ms, P¼0.001).
Conclusions: Intravenous amiodarone suppressed the electrical storm and decreased the QT and Tp–e
dispersions in patients treated by using CRT with a deﬁbrillator.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Cardiac resynchronization therapy (CRT) reduces mortality
and morbidity in selected heart failure patients with impaired
left ventricular (LV) function and cardiac dyssynchrony [1]. Most
patients receive CRT with a deﬁbrillator (CRT-D) because the
indications for an implantable cardioverter-deﬁbrillator (ICD)
overlap with those for CRT. Electrical storm, which is commonly
deﬁned as the occurrence of 3 or more separate episodes of
ventricular tachyarrhythmia requiring ICD therapies within 24 h
[2], is associated with worse heart failure-related morbidity and
survival among patients who receive CRT-D [3,4].
CRT may increase LV transmural dispersion of repolarization,
leading to ventricular tachyarrhythmia and electrical storm
induced by epicardial LV pacing [4–6]. Moreover, some reports
have demonstrated that ICD shocks alone can cause an increase in
QT dispersion, which may contribute to the proarrhythmic effects
of ICD shocks such as electrical storm [7,8]. Myocardial ischemia
increases the dispersion of repolarization and may result in shock-
induced arrhythmia [9,10].
Intravenous amiodarone is widely used in the treatment of
electrical storm [2]. However, few clinical studies have evaluated
the effect of intravenous amiodarone on the spatial and trans-
mural dispersion of ventricular repolarization in patients treated
with CRT.
The aim of this study was to evaluate the effect of intravenous
amiodarone on the electrocardiographic parameters of dispersion
of ventricular repolarization in patients with nonischemic heart
failure treated with CRT-D and electrical storm.
2. Methods
We studied 14 patients treated with CRT-D who were admitted
to our hospital because of electrical storm (Table 1). Patients who
were in atrial ﬁbrillation were excluded. Amiodarone diluted with
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5% glucose was administered as a loading dose of 2.0 mg/kg for
10 min and was subsequently infused continuously as a main-
tenance dose of 0.5 mg/kg/h. Twelve-lead electrocardiography
(ECG) was performed by using a standard digital recorder (Cardi-
ofaxV, Nihon Kohden Co., Tokyo, Japan) at a gain of 20 mm/mV
and a speed of 50 mm/s; a 187-channel repolarization interval-
difference mapping electrocardiograph (187-ch RIDM-ECG, Fukuda
Denshi Co. Ltd., Tokyo, Japan) was also used. The data from both
procedures were recorded before and during the intravenous
infusion of amiodarone. Additionally, blood samples were drawn
to assess the concentration of amiodarone in the patients' plasma.
This study was approved by the institutional review board of the
Tokyo Women's Medical University (approval no. 2036), and all
patients provided written informed consent.
The QT intervals and T-peak to T-end (Tp–e) intervals were
measured by using leads II and V2 of the 12-lead ECG. The QT
interval was obtained from the onset of the QRS complex to the
end of the T wave. The corrected QT interval (QTc) was calculated
using the Bazett formula. QT dispersion was deﬁned as the
difference between the maximum and minimum QT intervals of
the 12 ECG leads. The Tp–e interval was obtained from the peak of
the T wave to the end of the T wave, which corresponded to the
bottom of the T wave in cases of negative or biphasic T waves.
The Tp–e dispersion was obtained by assessing the difference
between the maximum and minimum Tp–e intervals of the 12
ECG leads (Fig. 1). Measurements of the recovery time (RT) and
Tp–e intervals according to the results of the 187-ch RIDM-ECG
were previously described in detail [7], and the corrected RT and
corrected Tp–e intervals were calculated by using the Bazett
formula. The maximum inter-lead differences between corrected
RT intervals and between corrected Tp–e intervals were automa-
tically calculated based on the difference between the maximum
and minimum values in this system. The corrected RT and Tp–e
interval difference maps were displayed as a color-coordinated
map according to time differences.
The data are presented as the mean7SD. The parameters were
compared before and during the intravenous amiodarone infusion
by using the Mann–Whitney U test, and a P-value o0.05 was
considered signiﬁcant.
3. Results
Among the 14 patients who received intravenous amiodarone for
the treatment of electrical storm, 1 patient received an inotropic
agent (intravenous dopamine) and 2 patients received a sedative
agent concomitant with the administration of intravenous amiodar-
one. The other patients continued to receive the same dose of beta-
blockers and other cardiovascular drugs during the intravenous
amiodarone treatment as they did prior to treatment. Ventricular
tachyarrhythmia that required ICD shock recurred in 2 patients after
the initiation of amiodarone infusion but it was not observed after
the initial 16 h of continuous infusion. No recurrence of ventricular
tachyarrhythmia that required ICD therapy occurred in the other
patients during the intravenous amiodarone infusion. The mean
treatment period of intravenous amiodarone was 105798 h. The
results of the 12-lead ECG and the 187-ch RIDM-ECG recorded during
the intravenous amiodarone infusion were obtained 26719 h after
the start of therapy.
The 12-lead ECG and 2-dimensional geometrical maps for cor-
rected RT interval difference and corrected Tp–e interval difference
obtained by using 187-ch RIDM-ECG before and during the intrave-
nous amiodarone infusion for representative cases are shown in
Figs. 1 and 2 respectively. The mean value of QTc measured by using
the 12-lead ECG increased during the intravenous administration of
amiodarone. By contrast, the maximum value of the QT interval
among the 12 leads decreased, and its minimum value increased
during the intravenous administration of amiodarone. Although the
mean value of the Tp–e interval measured by using the 12-lead ECG
was not affected during the intravenous administration of amiodar-
one, the maximum value of the Tp–e interval among the 12 leads
decreased, and its minimum value increased during the intravenous
administration of amiodarone. Additionally, QT dispersion and Tp–e
dispersion signiﬁcantly decreased during the intravenous amiodar-
one administration. The maximum inter-lead difference between
the corrected Tp–e intervals, but not the corrected RT intervals, as
measured by using 187-ch RIDM-ECG, signiﬁcantly decreased during
the intravenous infusion of amiodarone (Table 2).
These effects of intravenous amiodarone on ECG parameters
were similar between the patients who received and those who
did not receive prior oral amiodarone treatment (Table 2).
4. Discussion
This study showed that intravenous amiodarone mostly sup-
pressed ventricular tachyarrhythmia and increased the QTc, but not
the Tp–e interval. Moreover, intravenous amiodarone decreased QT
dispersion, Tp–e dispersion, and the maximum inter-lead difference
between the corrected Tp–e intervals, as measured by using the 187-
ch RIDM-ECG, in patients with CRT-D and electrical storm. Among
our patients, prior oral amiodarone therapy did not affect the change
in QT dispersion, Tp–e dispersion, or maximum inter-lead difference
between the corrected Tp–e intervals before or during the intrave-
nous amiodarone treatment.
Amiodarone is capable of modifying the activation pattern of
the ventricle during biventricular pacing in patients receiving CRT
because it affects both ventricular depolarization and repolariza-
tion. This may be reﬂected in the repolarization parameters of ECG,
such as the QT interval. Interestingly, intravenous amiodarone
treatment decreased the maximum QT and Tp–e intervals and
increased the minimum QT and Tp–e intervals. These effects of
amiodarone on ECG parameters might not be due to an equal
Table 1
Baseline characteristics in 14 nonischemic heart failure patients and electrical
storm treated with CRT-D.
Men (n) 11
Age (years) 67712
Indication for ICD
Secondary prevention 10
Primary prevention 4
Underlying heart disease
Idiopathic dilated cardiomyopathy 8
End-stage hypertrophic cardiomyopathy 3
Other 3
NYHA functional class on admission
II/III/IV 8/4/2
LVEF (%) 2773
Plasma BNP (pg/mL) 6177547
eGFR (mL/min/1.73 m2) 52.5739.0
Medications on admission
Beta-blockers 12
ACE inhibitors/ARBs 12
Spironolactone 8
Loop diuretics 11
Amiodarone 8
Values are represented as n or mean7SD.
ICD, implantable cardioverter-deﬁbrillator; CRT-D, cardiac resynchronization ther-
apy with ICD; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; BNP, brain natriuretic peptide; eGFR, estimated glomerular ﬁltration
rate; ACE, angiotensin-converting enzyme; and ARB, angiotensin II receptor
blocker.
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decrease in transmural dispersion of repolarization at any region
in the ventricle; instead, they might be the results of counter-
balancing the heterogeneity of ventricular repolarization.
A signiﬁcant decrease in QT dispersion, Tp–e dispersion, and maxi-
mum inter-lead difference between corrected Tp–e intervals (by
using 187-ch RIDM-ECG) supports the hypothesis that intravenous
amiodarone decreases the spatial dispersion of ventricular
repolarization.
The mean value of the inter-lead difference between corrected
RT intervals determined by using 187-ch RIDM-ECG decreased
Fig. 1. ECG readings. Representative 12-lead ECG (50 mm/s) images before and during intravenous administration of amiodarone infusion in a patient with CRT-D and
electrical storm. The results of the patient were set to an AV delay of 150 ms and a VV delay of 45 ms. QT dispersion¼maximum QT intervalminimum QT interval among 12
leads. Tp–e dispersion¼maximum Tp–e intervalminimum Tp–e interval among 12 leads.
Fig. 2. Interval difference maps. Representative corrected RT interval difference map and corrected Tp–e interval difference map before and during intravenous
administration of amiodarone infusion in a patient with CRT-D and electrical storm. The results of the patient were set to an AV delay of 140 ms and a VV delay of
20 ms. The differences from the smallest corrected RT interval or corrected Tp–e interval were scaled according to color, with blue indicating o40 ms, yellow indicating 40–
60 ms, and red indicating 460 ms. Maximum inter-lead difference between corrected RT intervals¼maximum corrected RT intervalminimum RT interval. Maximum
inter-lead difference between corrected Tp–e intervals¼maximum Tp–e intervalminimum Tp–e interval (measured on the 187-ch RIDM-ECG image).
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during the intravenous administration of amiodarone, but this
difference was not statistically signiﬁcant. In contrast, QT disper-
sion on the 12-lead ECG signiﬁcantly decreased. The RT interval
was deﬁned as the time difference between the R-wave peak and
the T-wave peak of the relative electrical current density of the
variable-moment dipole current, which was calculated from the
187-channel electrical potentials on the basis of the Coulomb Law
[11,12]. Therefore, the R-wave and T-wave peaks on the 187-ch
RIDM-ECG images were not identical to those on the 12-lead ECG
image. The inter-lead difference between the corrected RT inter-
vals obtained from the 187-ch RIDM-ECG image may be less likely
to be modiﬁed by the effect of amiodarone on depolarization and
repolarization of the ventricle.
The acute effects of amiodarone are the blockade of the L-type
calcium inward current; the sodium inward current (INa), with a
high afﬁnity for its inactivated state; and the rapid and slow
components of the delayed rectiﬁer potassium current (IKr and IKs).
In contrast, its chronic effect is mediated by prolonging the action
potential duration (APD) through a decrease in the potassium
channel density, especially IKs and transient outward current [13].
A single intravenous bolus of amiodarone does not prolong the
QRS duration or QTc in humans, as observed on ECG [14,15]. In an
experimental study, amiodarone produced little change in the APD
of epicardial and endocardial tissues, but it shortened the APD of
the M-region tissue via the blockade of late INa, leading to a
decrease in the transmural dispersion of repolarization in the
Table 2
Electrocardiographic parameters before and during intravenous amiodarone infusion in 14 nonischemic heart failure patients and electrical storm treated with CRT-D.
Before amiodarone During amiodarone P value
12-Lead ECG
RR (ms) 8707101 851789 0.593
QRS duration (ms) 149720 165721 0.003
QTc (ms) 470752 508755 0.003
Maximum QT (ms) 510749 478737 0.006
Minimum QT (ms) 403734 429739 0.006
QT dispersion (ms) 107735 49727 0.001
Tp–e (ms) 101718 107718 0.217
Max Tp–e (ms) 145727 121728 0.027
Minimum Tp–e (ms) 59718 92712 0.001
Tp–e dispersion (ms) 86717 28728 0.001
Prior oral amiodarone (þ), n¼8
RR (ms) 8467102 811753 0.362
QRS duration (ms) 148723 168722 0.017
QTc (ms) 469758 522764 0.025
Maximum QT (ms) 506751 478743 0.049
Minimum QT (ms) 396741 426745 0.030
QT dispersion (ms) 111736 51724 0.012
Tp–e (ms) 103717 114719 0.125
Max Tp–e (ms) 148726 131732 0.235
Minimum Tp–e (ms) 65719 98712 0.012
Tp–e dispersion (ms) 84713 34735 0.017
Prior oral amiodarone (), n¼6
RR (ms) 903790 905799 0.785
QRS duration (ms) 152716 161720 0.066
QTc (ms) 472743 491733 0.043
Maximum QT (ms) 515747 480728 0.043
Minimum QT (ms) 412719 433729 0.068
QT dispersion (ms) 103732 46730 0.043
Tp–e (ms) 100718 98712 0.891
Maximum Tp–e (ms) 142728 106710 0.042
Minimum Tp–e (ms) 53713 8578 0.042
Tp–e dispersion (ms) 89720 21713 0.027
187-ch RIDM-ECG
Inter-lead difference between corrected RT (ms) 83719 68726 0.064
Inter-lead difference between corrected Tp–e (ms) 83713 50719 0.001
Prior oral amiodarone (þ), n¼8
Inter-lead difference between corrected RT (ms) 87719 69728 0.176
Inter-lead difference between corrected Tp–e (ms) 86714 47724 0.012
Prior oral amiodarone (), n¼6
Inter-lead difference between corrected RT (ms) 78718 68722 0.248
Inter-lead difference between corrected Tp–e (ms) 8079 5477 0.028
Plasma drug concentration
Prior oral amiodarone (þ), n¼8
Amiodarone (mg/mL) 0.3670.36 1.6770.79
Desethylamiodarone (mg/mL) 0.3670.33 0.7470.27
Prior oral amiodarone (), n¼6
Amiodarone (mg/mL) – 1.4570.69
Desethylamiodarone (mg/mL) – 0.5170.32
Values are represented as mean7SD.
ECG, electrocardiography; QTc, corrected QT interval; RT, recovery time; Tp–e; T peak–T end; and 187-ch RIDM-ECG, 187-channel repolarization interval-difference mapping
electrocardiograph.
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canine ventricle [16]. The results of another experimental study
revealed that amiodarone suppressed inducible arrhythmia, with a
decrease in the Tp–e and the transmural dispersion of APD
secondary to the inhibition of both the IKr and the late INa at high
concentrations of the drug (1–10 mM) in rabbit heart in which the
late INa was augmented in the presence of sea anemone toxin [17].
Although the mechanisms are not well understood, the acute
effect of amiodarone in inhibiting the late INa and counterbalan-
cing APD prolongation through the inhibition of IKr may play a role
in the beneﬁcial effect of repolarization on LV spatial and trans-
mural dispersion in patients with heart failure.
A recurrence of ventricular arrhythmia requiring ICD therapy
was observed in 2 patients during the early period of intravenous
amiodarone therapy. This recurrence may be due to the slow
uptake of amiodarone into heart tissue because of its pharmaco-
kinetic characteristics, which also accounts for its delayed antiar-
rhythmic effects [14]. In this study, we observed the pharmaco-
logical effect of amiodarone on the parameters of dispersion of
ventricular repolarization, but it was unclear whether these effects
were closely related to the therapeutic value of amiodarone for
suppression of ventricular arrhythmias, such as electrical storm. To
clarify this issue, further clinical investigation is necessary.
In conclusion, intravenous amiodarone suppressed electrical
storm and decreased QT and Tp–e dispersions in patients with
nonischemic heart failure treated with CRT-D and electrical storm.
These effects may partially result from a decrease in spatial
dispersion of ventricular repolarization.
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